VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Active, not recruiting · NCT03690986 · Registry updated 2026-07-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 | 2026-07-16 | NCT03690986 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| Vaccinex Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Hospital Midtown | Atlanta | United States | 246 |